Financing ·
Apollomics Inc. entered into subscription agreements for a private placement of up to 700,001 Class A ordinary shares…
APLMApollomics Inc.
Apollomics Inc. entered into subscription agreements for a private placement of up to 700,001 Class A ordinary shares expected to close on August 14, 2026. The transaction generates approximately $10 million in aggregate gross consideration, comprising $8 million in cash proceeds from the sale of 533,334 shares at $15.00 per share and the conversion of a $2 million convertible promissory note held by CEO Hung-Wen (Howard) Chen into 166,667 shares at $12.00 per share. Participants include executive officers and directors, constituting related-party transactions approved by the independent Audit Committee. Net proceeds will fund clinical development, working capital, and general corporate purposes. Apollomics Inc. is a late-stage clinical biopharmaceutical company developing oncology drug candidates to address difficult-to-treat cancers.